88 stories mentioning BSXUpdated 43m ago
Every FINWIRES story that references BSX, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Boston Scientific (BSX) shares were down over 1% in Thursday trading after Citigroup downgraded the stock to neutral from buy, and cut its price target to $50 from $57.Trading volume stood at more than 16.1 million shares, compared with a daily average of about 20.4 million.Price: $43.35, Change: $-0.56, Percent Change: -1.29%
Boston Scientific (BSX) has an average rating of buy and mean price target of $60.67, according to analysts polled by FactSet.
Boston Scientific (BSX) has an average rating of buy and mean price target of $60.67, according to analysts polled by FactSet.
(Updates with market moves at the end of the day, and other changes, if any.)US stocks fell for a second consecutive session on Tuesday as heightened tensions in the Middle East drove oil prices higher.The Dow Jones Industrial Average closed 1.2% lower at 52,786.07, while the S&P 500 shed 0.6% to 7,673.52. The Nasdaq Composite dipped 0.3% to 26,421.41. US markets were closed Monday for the Labor Day holiday.Most sectors ended in the red, led by healthcare, while energy paced the gainers.West Texas Intermediate crude oil rose 2.4% to $93.71 a barrel in Tuesday late-afternoon trade, having hit a high of $94.73 earlier in the day. Brent crude climbed 1.9% to $98.79, after advancing earlier to reach an intraday peak of $99.46.Yemen's Iran-allied Houthi group struck civilian and economic sites in Saudi Arabia, injuring 73 people, the kingdom's Ministry of Foreign Affairs said Tuesday. The Houthi group targeted Saudi Aramco's facilities across Abha, Najran, and Jazan, Bloomberg News reported, citing the group's military spokesperson.US Central Command said Saturday that its forces targeted three Iranian oil tankers on Saturday in response to Tehran firing ballistic missile at two American Navy warships.Treasury yields were higher, with the two-year rate up 1.7 basis points at 4.4% and the 10-year rate rising 0.8 basis point to 4.79%.US consumers had mixed views on the inflation trajectory in August, seeing prices hold steady in the short- and long-term but expecting a drop over the next three years, a survey by the Federal Reserve Bank of New York showed Tuesday.The August consumer and producer price data for August, due out later this week, could serve as crucial data points for the Federal Open Market Committee, which begins its two-day policy meeting Tuesday next week.Markets are pricing in a 59% probability that the FOMC will raise the benchmark lending rate by 25 basis points on Sept. 16, with the remaining odds pointing to another Fed pause, according to the CME FedWatch tool.In company news, Boston Scientific (BSX) shares fell 5.9% after the medical device maker said it may not be able to meet its own guidance, citing a "material impact" from a recent cybersecurity incident.ABM Industries (ABM) tightened its full-year earnings outlook as the facility services provider's bottom line for the fiscal third quarter topped market estimates. The company's shares jumped 7.6%.S&P 500 companies' second-quarter earnings growth continues to outpace early forecasts as the reporting season draws to a close, Oppenheimer Asset Management said Tuesday.Cloud computing giant Oracle (ORCL) and photoshop maker Adobe (ADBE) are scheduled to report results later in the week.Spot gold dropped 1.1% to $4,357.46 per troy ounce, while silver edged down 0.4% to $66.50 per ounce.
Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.2%.The iShares Biotechnology ETF (IBB) shed 1.9%.In corporate news, Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "material impact" from a recent cybersecurity incident. Boston Scientific shares were down 5%.Novartis (NVS) shares fell past 13% after it said a phase 3 trial assessing delpacibart etedesiran in people with myotonic dystrophy type 1 failed to meet its primary endpoint.GSK (GSK) is raising $6.5 billion from a US high-grade debt sale to help refinance bridge funding for its $10.6 billion takeover of Nuvalent, Bloomberg reported. GSK shares fell 2.4%.Novo Nordisk (NVO) has stopped two additional trials of its experimental cardiovascular drug, ziltivekimab, after an independent committee found a low chance they would produce a different result from an earlier failed study, Reuters reported. The trials, which tested the drug in heart failure patients, will end early, the company told. It added that patients will continue through to their 3-months follow-up as already planned. Novo shares were shedding 2.7%.
Boston Scientific's (BSX) cyberattack could extend the timeframe for a sustainable stock rebound, but the company still offers relative risk/reward skewed to the upside over the next six to 12 months, Truist Securities said in a note Tuesday.The company earlier said it is unlikely to meet its Q3 and full-year 2026 net sales growth and adjusted earnings per share guidance ranges.Truist said the cyberattack's impact on revenue and EPS remains unframed, while recent company updates indicate that the distribution network has been substantially restored and manufacturing has resumed across most facilities globally.Truist said 2026 and likely 2027 estimates will need to come down, with the Q3 earnings call in October the next likely official guidance update.The brokerage expects upcoming investor presentations to provide additional information on the cyberattack recovery pathway, affected business segments and potential share loss or recapture.Truist maintained a buy rating and a $57 price target.Price: $44.97, Change: $-2.83, Percent Change: -5.93%
(Updates with latest market prices and developments.)US benchmark equity indexes were lower intraday, while oil prices were volatile amid intensifying tensions in the Middle East.The Dow Jones Industrial Average was down 1% at 52,875.1 after midday Tuesday, while the S&P 500 fell 0.3% to 7,692.4. The Nasdaq Composite edged down 0.1% to 26,484.7. The indexes finished Friday's trading session in the red.US markets were closed Monday for the Labor Day holiday.Among sectors, healthcare led the laggards intraday Tuesday, while utilities paced the gainers.West Texas Intermediate crude oil rose 0.7% to $92.09 a barrel, having hit a high of $94.73 earlier in the day. Brent crude edged down 0.1% to $96.90, after advancing earlier to reach an intraday peak of $99.46.Yemen's Iran-allied Houthi group struck civilian and economic sites in Saudi Arabia, injuring 73 people, the kingdom's Ministry of Foreign Affairs said Tuesday. The Houthi group targeted Saudi Aramco's facilities across Abha, Najran, and Jazan, Bloomberg News reported, citing the group's military spokesperson.The attacks were in retaliation to Saudi strikes in northwestern Yemen, BBC reported, citing the Houthis.The US Treasury Department said Tuesday it "sanctioned 36 targets for supporting Iran's aviation sector, which the regime uses to move weapons, personnel, and illicit cargo."Treasury yields were little changed intraday, with the two-year rate at 4.38% and the 10-year rate at 4.79%.In company news, Boston Scientific (BSX) shares fell 4.7% after the medical device maker flagged its inability to meet its third-quarter and full-year financial outlooks, citing a "material impact" from a recent cybersecurity incident.ABM Industries (ABM) tightened its full-year earnings outlook as the facility services provider's bottom line for the fiscal third quarter topped market estimates. The company's shares were up 7.8%.S&P 500 companies' second-quarter earnings growth continues to outpace early forecasts as the reporting season draws to a close, Oppenheimer Asset Management said Tuesday.Cloud computing giant Oracle (ORCL) and Photoshop maker Adobe (ADBE) are scheduled to report results later in the week.Spot gold ticked down 0.2% to $4,393.97 per troy ounce, while silver rose 0.5% to $67.06.
Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "material impact" from a recent cybersecurity incident, sending the medical device maker's shares lower Tuesday.The incident, which the company identified Aug. 25, affected some of its information technology systems and caused a network outage that impacted its ability to manufacture, process and ship customer orders.Boston Scientific expects the incident to have a "material impact" to its third-quarter and 2026 operational results, prompting the company to flag the potential guidance miss for both periods, according to a filing with the US Securities and Exchange Commission Tuesday.Boston Scientific shares were down 5.6% in afternoon trade, bringing its year-to-date losses to nearly 53%.In July, the company said it anticipated third-quarter adjusted earnings of $0.80 to $0.82 a share on net sales growth of 3% to 5%. For the full year, Boston Scientific projected adjusted EPS at $3.28 to $3.32 on sales growth of 5.5% to 6.5%.The current consensus on FactSet is for non-GAAP EPS of $0.81 and sales to increase by 3.8% for the third quarter, while 2026 non-GAAP EPS is pegged at $3.30, with sales seen rising 6.3%.Boston Scientific expects to recover "some portion" of the impacted revenue as it continues to ramp its global operations, fulfill customer orders, and reduce its remaining backlogs, it said Tuesday. The company continues to make progress in restoring most of its affected systems, with major distribution centers now processing and shipping orders "at or above" normal levels, it said in the filing. Boston Scientific intends to fully restore all of its systems, but said a timeline for a full-scale recovery is uncertain.Separately, Truist Securities said the cyberattack has come at a "vulnerable time" for the company."We think there's limited downside at these levels, and continue to think that (Boston Scientific) has growth acceleration on tap by (the second half of 2027-2028) with attractive end-(markets) and a rich pipeline that are not adequately reflected in the valuation," the brokerage said in a note to clients.In July, the company cut its full-year outlook amid weaker-than-expected demand for its Watchman heart implant and competitive pressure in the US electrophysiology market.Boston Scientific plans to provide an updated operational and financial outlook, incorporating the expected impact of the incident, when it reports third-quarter results Oct. 28, it said Tuesday.The incident follows a March cyberattack on rival medical-device maker Stryker (SYK) that disrupted its order processing, manufacturing and shipping. In April, the company said the attack materially affected its first-quarter results.Price: $45.30, Change: $-2.51, Percent Change: -5.24%
Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.2%.The iShares Biotechnology ETF (IBB) shed 1.8%.In corporate news, Novartis (NVS) shares fell past 13% after it said a phase 3 trial assessing delpacibart etedesiran in people with myotonic dystrophy type 1 failed to meet its primary endpoint.Boston Scientific (BSX) identified a cybersecurity incident affecting some information technology systems that resulted in a global disruption of its operations. The company expects to recover part of the affected revenue but said it is unlikely to meet its net sales growth and adjusted EPS guidance ranges for Q3 and the full year. Boston Scientific shares were down 5.1%.Novo Nordisk (NVO) has stopped two additional trials of its experimental cardiovascular drug, ziltivekimab, after an independent committee found a low chance they would produce a different result from an earlier failed study, Reuters reported. The trials, which tested the drug in heart failure patients, will end early, the company told. It added that patients will continue through to their 3-months follow-up as already planned. Novo shares were shedding 2.7%.
All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and investors monitored developments in the US-Iran war and US trade negotiations with Canada.In company news, GE Aerospace (GE) agreed to acquire Consolidated Precision Products from Warburg Pincus and Berkshire Partners for $11.75 billion. GE shares rose 0.5% around midday.Qualcomm (QCOM) issued a warrant to an Amazon.com (AMZN) affiliate last week to acquire up to 25 million shares at $161.26 each, the chipmaker said. Qualcomm is also collaborating with Amazon to produce customized silicon for large-scale AI data centers and optical connectivity products. Qualcomm shares rose 4.6%, and Amazon fell 0.5%.Novartis (NVS) said its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time. Separately, Monte Rosa Therapeutics (GLUE) will receive a $50 million milestone payment from Novartis after initiating a phase 2 clinical trial of MRT-6160 to treat Sjogren's disease. Novartis shares slumped 13%, and Monte Rosa rose 1.7%.Boston Scientific (BSX) identified a cybersecurity incident affecting certain information technology systems that resulted in a global disruption of its operations. The company expects to recover part of the affected revenue but said it is unlikely to meet its net sales growth and adjusted EPS guidance ranges for Q3 and the full year. Boston Scientific shares fell 4.6%.Meta Platforms (META) has run over 300 paid advertisements allegedly containing child sexual abuse material this year, according to an investigation by the Tech Transparency Project, a nonprofit watchdog organization. Hours after TTP shared its findings with the company, Meta removed about 150 of the ads that were still visible in its database of advertising that has run on its platforms, the group said. Meta shares were little changed.Amgen (AMGN) said its phase 3 DeLLphi-305 study met its primary endpoint with Imdelltra in combination with AstraZeneca's (AZN) Imfinzi, showing a statistically significant and clinically meaningful improvement in overall survival in patients with extensive-stage small cell lung cancer. Amgen shares still fell 9.6%, and AstraZeneca dropped 0.9%.Price: $338.76, Change: $+1.63, Percent Change: +0.48%
Healthcare stocks were lower pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) and the State Street Health Care Select Sector SPDR ETF (XLV) both down by 1.3%.Novartis (NVS) was down more than 12% after the company said its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time.Boston Scientific (BSX) shares were down more than 1% after the company said it is unlikely to meet its net sales growth and adjusted EPS guidance ranges for Q3 and 2026 due to a cybersecurity incident that led to a global disruption to its operations.Roivant Sciences' (ROIV) Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints, the company said. Roivant Sciences stock was up more than 17% pre-bell.
(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were mostly lower pre-bell Tuesday, coming off a three-day weekend as traders assessed rising oil prices and Canada's retaliatory tariffs against the US.Dow Jones Industrial Average futures were 0.7% lower, S&P 500 futures were down 0.2%, and Nasdaq futures were 0.2% higher.Canadian tariffs, which were announced after trade talks with the US collapsed last month, took effect on Tuesday and range from 15% to 50%, impacting hundreds of US products, including dairy, agricultural equipment, paper, household appliances and electronics.US President Donald Trump, in a Monday post on Truth Social, called for a boycott of Canadian aerospace manufacturer Bombardier, saying "If they want our Market, they must build here, and stop treating America like a 'piggybank'". In response, the company told CNBC that its workers are based all over the US, with sites in 10 states, while its aircraft are constructed using US-made components.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 1.1% at $98.04 per barrel and US West Texas Intermediate crude 1.7% higher at $93.01 per barrel.The National Federation of Independent Business' monthly Small Business Optimism Index fell to a reading of 98.7 in August from 99.8 in July.In other world markets, Japan's Nikkei closed 1.7% lower, Hong Kong's Hang Seng ended 0.4% lower, and China's Shanghai Composite finished 0.2% higher. Meanwhile, the UK's FTSE 100 was flat, and Germany's DAX index was flat in Europe's early afternoon session.In equities, Taiwan Semiconductor Manufacturing (TSM) and ASML (ASML) shares rose 1.8% and 3.8%, respectively, after the two companies said they are collaborating on a project to move chipmaking to larger numerical aperture extreme ultraviolet masks. Lockheed Martin (LMT) stock was up 1.3% after UBS upgraded the company's stock to buy from neutral and adjusted the price target to $674 From $581. Roivant Sciences (ROIV) shares were more than 20% higher after the company said its Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints.On the losing side, Novartis (NVS) stock dropped more than 12% after the company said its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time. Novo Nordisk (NVO) shares fell 1.8% after a Reuters report on Monday that the company has stopped two additional trials of its experimental cardiovascular drug, ziltivekimab, after an independent committee found a low chance they would produce a different result from an earlier failed study. Boston Scientific (BSX) stock was down 1.4% after the company said it is unlikely to meet its net sales growth and adjusted EPS guidance ranges for the third quarter and full year 2026 after identifying a cybersecurity incident that resulted in a global disruption to its operations.
The Standard & Poor's 500 index edged up 0.5% this week amid stronger-than-expected quarterly reports from tech companies including Salesforce (CRM) and CrowdStrike (CRWD).The S&P 500 ended the week at 7,711.76. With just one session remaining in the month, the market benchmark is up 3% for August and has climbed 13% this year.At the annual Jackson Hole Economic Policy Symposium, Federal Reserve Chairman Kevin Warsh reaffirmed his commitment to the Fed's mandates, including the 2% inflation goal. Warsh said inflation numbers were concerning, citing the Fed's preferred metric -- the personal consumption expenditure price index -- which was unchanged at 3.7% year over year in July.Data released earlier this week showed US economic growth, measured by gross domestic product, rose by 1.5% in Q2. This was unrevised from the advance estimate released last month and matched expectations in a survey compiled by Bloomberg.The University of Michigan consumer sentiment index was revised upward on Friday to 51.7 for August from 51.0 in the preliminary estimate, compared with expectations for no revision in a survey compiled by Bloomberg. The latest reading was still below July's final print of 55.2.The technology sector had the largest percentage increase this week, climbing 1.8%, followed by a 1.6% advance in communication services and a 1.1% rise in financials. Consumer discretionary eked out a 0.1% gain.Salesforce was the best performer in both the technology sector and the overall S&P 500 this week, jumping 22%. The company reported fiscal Q2 adjusted earnings and revenue above analysts' mean estimates and boosted its fiscal 2027 guidance.CrowdStrike had the second-largest percentage gain in technology and the overall S&P 500, climbing 14%. The company reported better-than-expected fiscal second-quarter results. CrowdStrike also raised its guidance for full-year net new annual recurring revenue, or ARR, amid increasing demand for cybersecurity solutions to address artificial intelligence risks.The health care and energy sectors fell 2% each, followed by a 1.7% decline in industrials and a 1.3% slip in real estate. Consumer staples, materials and utilities also edged lower.Boston Scientific (BSX) had the largest percentage loss in health care for the week, shedding 7%. The company is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration said.The decline in energy came as crude oil futures also fell on the week. Mediators in the Iran war are stepping up efforts to get the Strait of Hormuz reopened, Reuters reported. Top decliners in the sector included EOG Resources (EOG), which fell 6.3% amid an investment rating downgrade by Capital One to equal weight from overweight.Earnings reports next week are expected from companies including Palo Alto Networks (PANW), Dell Technologies (DELL), Medtronic (MDT), Broadcom (AVGO) and Snowflake (SNOW).Investors will be heavily focused on the government's August employment report, due Friday. Other reports will include July construction spending and factory orders.
Healthcare stocks fell late Wednesday afternoon, with the NYSE Healthcare Index shedding 1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.5%.In sector news, the Trump Administration is planning to announce a new round of drug-pricing agreements on Monday with several midsized biotech companies that would offer discounts to state Medicaid programs, Bloomberg reported. The companies would provide discounts so prices align with those charged in foreign markets and would be exempt from Medicare pilot programs requiring similar reductions, while tariff relief is part of some of the discussions, the report said.In corporate news, Eli Lilly (LLY) said Wednesday that a real-world study showed sustained use of its weight-management drug Zepbound was associated with lower healthcare costs among adults older than 55 with overweight or obesity, compared with similar untreated adults. Lilly shares were down 3.3%.Boston Scientific (BSX) is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement. Separately, Boston Scientific has identified a cybersecurity incident that affected some of its IT systems and led to global disruptions in operations, the company said Wednesday in a regulatory filing. Boston Scientific shares fell 3%.Revolution Medicines' (RVMD) Rasonque, or daraxonrasib, has been approved to treat metastatic pancreatic cancer, the US Food and Drug Administration said Wednesday. Revolution shares rose 0.4%.Biuohaven (BHVN) shares surged past 19% in Wednesday trading after the company signed a licensing and collaboration deal with SK Biopharmaceuticals for an investigational focal epilepsy treatment.
(Updates with share movement in the headline and the first paragraph.)Boston Scientific (BSX) shares fell 2.7% in Wednesday trading after the company recalled certain percutaneous catheters due to the risk of arterial sheath tip separation, which could lead to complications from a retained tip, according to the US Food and Drug Administration.The affected products are certain lots of the company's ENROUTE Transcarotid Neuroprotection System and ENROUTE Transcarotid Neuroprotection System Plus devices, according to the statement. The FDA warned that potential complications include embolism and stroke, among others.Boston Scientific has reported one serious injury related to the issue, the FDA said.Price: $48.52, Change: $-1.35, Percent Change: -2.70%
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.8%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Boston Scientific (BSX) is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement. Separately, Boston Scientific has identified a cybersecurity incident that affected some of its IT systems and led to global disruptions in operations, the company said Wednesday in a regulatory filing. Boston Scientific shares were down 3.3%.Revolution Medicines' (RVMD) Rasonque, or daraxonrasib, has been approved for the treatment of metastatic pancreatic cancer, the US Food and Drug Administration said Wednesday. Revolution shares rose 2.9%.Summit Therapeutics (SMMT) partner Akeso reported "positive" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Summit shares jumped past 8%.
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.8%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Boston Scientific (BSX) is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement. Separately, Boston Scientific has identified a cybersecurity incident that affected some of its IT systems and led to global disruptions in operations, the company said Wednesday in a regulatory filing. Boston Scientific shares were down 3.1%.
All three major US stock indexes were down slightly in late-morning trading Wednesday, as market participants took in the latest inflation data and prepared for Nvidia (NVDA) to release its earnings results after markets close.The personal consumption expenditures index, a measure of inflation, rose by 0.2% in July, faster than the 0.1% gain expected in a survey conducted by Bloomberg as of 6:10 am ET and following a 0.1% drop in June. The July figure keeps the year-over-year rate at 3.7%. The core PCE index, which excludes food and energy prices, increased by 0.2%, as expected and following a 0.1% gain in June. The year-over-year rate remained at 3.3% in the month.Separately, US gross domestic product rose by 1.5% in Q2, unrevised from the advance estimate released last month and matching the consensus estimate from a Bloomberg survey as of 6:10 am ET.In company news, Meta Platforms (META) has agreed to pay a maximum of $16.68 billion to resolve claims brought by several US states that the tech giant used its platforms to "ensnare" youth and teens, according to a Wednesday filing in federal court. The consent agreement's injunctive relief also requires Meta to take several steps to regulate children's usage of its social media platforms, including daily limits and nighttime blocks. In a separate release, Meta said the agreement includes a payment of about $18 billion to be distributed in annual installments over a 10-year period. Plaintiff states will receive about $12.7 billion over the decade, while the remaining roughly 30%, or $5.3 billion, will be released if Alphabet's (GOOG, GOOGL) YouTube and TikTok "implement a one-hour Daily Limit, Night Mode, and Age assurance measures," and they each pay an amount equal to the 30% figure. Meta shares were up 2.1% around midday. Alphabet's Class C and Class A shares were down 1.1% and 1.2%, respectively.Victory Capital (VCTR) signed a definitive agreement to acquire First Eagle Investments from Genstar Capital and First Eagle employees for about $7 billion, Victory said Wednesday. Victory will pay about $4.4 billion in cash, $2 billion in newly issued shares and will assume $575 million of First Eagle's existing 7.25% senior secured notes due 2032, the company said. The deal is expected to close in Q1 2027, at which point Genstar will own a 14.6% stake in Victory, the company said. Victory Capital shares were up 6.3%.Intuit (INTU) reported fiscal Q4 adjusted earnings late Tuesday of $4.03 per diluted share, up from $2.75 a year earlier and above the FactSet consensus of $3.58. Fiscal Q4 revenue was $4.35 billion, up from $3.83 billion a year ago and above the FactSet consensus of $4.27 billion. For fiscal Q1, the company expects adjusted EPS of $2.44 to $2.48 on revenue of $4.29 billion to $4.31 billion. Analysts polled by FactSet expect $4.04 and $4.35 billion, respectively. For fiscal 2027, Intuit expects adjusted EPS of $22.88 to $23.12 on revenue of $23.28 billion to $23.51 billion. Analysts expect $27.34 and $23.70 billion, respectively. The company raised its quarterly dividend to $1.38 per share from $1.20, payable on Oct. 16. Intuit shares were down 4.5%.Boston Scientific (BSX) identified a cybersecurity incident that affected some of its IT systems and led to global disruptions in operations, the company said Wednesday in a regulatory filing. Boston Scientific shares were down 4.7%.Amazon (AMZN), Microsoft (MSFT) and Alphabet's Google are in talks with Chinese AI startup Moonshot AI over revenue-sharing deals for hosting Moonshot's Kimi K3 model, Reuters reported Wednesday, citing sources familiar with the matter. Separately, Amazon plans to expand fulfillment capacity, same-day delivery and its logistics network in Canada despite escalating trade tensions between the US and Canada, Business Insider reported Wednesday, citing internal company documents. Lastly, Amazon's AWS unit is acquiring DuckLabs, the Amsterdam-based company behind the open-source analytical database DuckDB, for an undisclosed sum, Amazon said. The deal is expected to close shortly, Amazon said. Shares of Amazon were down 0.6%, and Microsoft was up 0.7%.Price: $582.24, Change: $+12.19, Percent Change: +2.14%
Boston Scientific (BSX) is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement.The affected products are certain lots of the company's ENROUTE Transcarotid Neuroprotection System and ENROUTE Transcarotid Neuroprotection System Plus devices, according to the statement. The FDA warned that potential complications include embolism and stroke, among others.Boston Scientific has reported one serious injury related to the issue, the FDA said.Price: $47.67, Change: $-2.20, Percent Change: -4.40%
Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) declining by 0.5%.Boston Scientific (BSX) has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.Jazz Pharmaceuticals' (JAZZ) wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.Summit Therapeutics (SMMT) partner Akeso reported "positive" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.
Showing 1-20 of 88
